Ozempic and Eyesight: What the Latest Safety Warnings Mean in November 2026

Information checked: November 10, 2026, at 1:08 p.m. UTC (UTC+00:00).

US regulators have called for new warnings about a rare condition that can cause sudden vision loss in people taking GLP-1 medicines, including Ozempic. On November 9, 2026, the Food and Drug Administration (FDA) said the drugs may increase the risk of non-arteritic anterior ischemic optic neuropathy, or NAION, and required manufacturers to add information to the warnings and precautions sections of their labels.

For people in the UK, the practical advice is already clear: sudden vision loss or rapidly worsening eyesight during semaglutide treatment needs urgent assessment at an eye casualty department, if available, or an accident and emergency department (A&E). The UK Medicines and Healthcare products Regulatory Agency (MHRA) says NAION has been linked to semaglutide very rarely and that treatment should be stopped if the diagnosis is confirmed.

Destaques

• NAION can cause sudden, usually painless loss of vision, typically in one eye, and the loss can be permanent.
• The FDA's new action covers the GLP-1 drug class; the UK warning discussed here concerns semaglutide, the ingredient in Ozempic, Wegovy and Rybelsus.
• The MHRA estimates that NAION may affect up to one in 10,000 people taking semaglutide; individual risk cannot be predicted from that figure alone.
• Without sudden symptoms, discuss concerns and any treatment changes with your prescriber. If vision suddenly deteriorates, seek urgent eye care.

What is the new FDA warning about Ozempic and eyesight?

In its November 9 safety communication, the FDA said it had found a potential increased risk of NAION associated with GLP-1 receptor agonists. It is requiring application holders to add information about that potential risk to the warnings and precautions section of labeling for all medicines in the class.

Ozempic contains semaglutide and is prescribed for type 2 diabetes. Semaglutide is also the active ingredient in Rybelsus, another diabetes medicine, and Wegovy, used for weight management and cardiovascular risk reduction in eligible patients. The FDA action is a US regulatory decision; it does not itself change UK prescribing rules.

The MHRA's February 2026 safety update addressed semaglutide specifically. It advised urgent specialist examination for sudden vision loss, including partial loss, and discontinuation of semaglutide if NAION is confirmed. The MHRA said its review did not include other GLP-1 agonists and that it was reviewing evidence concerning them.

What is NAION, and what symptoms should people notice?

NAION affects the optic nerve, which carries visual information from the eye to the brain. It occurs when blood flow to the front of the nerve is reduced. Vision loss often appears suddenly, without pain, and usually affects one eye at a time. It can be noticed on waking.

Symptoms can include cloudy or blurred vision, a missing area of the visual field, changes in color perception or reduced sharpness. These symptoms do not establish that a person has NAION: other eye and neurological problems can also require urgent care. The important step is to seek assessment promptly, including for a partial loss of vision.

The MHRA advises people taking semaglutide to attend eye casualty, if available locally, or A&E urgently if they experience sudden vision loss or eyesight that worsens very quickly in one or both eyes. Tell the clinician which medicines you take, including any semaglutide obtained through a private prescription.

How strong is the evidence, and how rare is the risk?

Regulators have considered several kinds of evidence, including clinical trials and studies of medical records. The European Medicines Agency's safety review concluded in 2025 that NAION is a very rare side effect of semaglutide. The MHRA subsequently described it as a very rare possible side effect and noted conflicting evidence in the literature.

Several large observational studies reviewed by European regulators suggested that adults with type 2 diabetes taking semaglutide had roughly twice the relative risk of NAION compared with people not taking it. The estimated difference was about one additional case for every 10,000 people treated for one year. A doubling of relative risk can sound large, but it starts from a low baseline; that estimate is not a prediction for any individual.

The FDA also analyzed 126 randomized trials across GLP-1 medicines. It found 10 probable NAION events among participants taking a GLP-1 drug and five among those receiving a comparison treatment. The reported rates were 6.4 and 3.8 events per 100,000 person-years, respectively. A person-year is a measure combining the number of people observed and the length of their follow-up. These results cover the drug class and should not be read as an Ozempic-only estimate.

NAION is rare, so even large studies can contain few cases. Observational research can identify an association but cannot by itself prove that a medicine caused a particular patient's vision loss. Diabetes, high blood pressure, smoking and other factors can also raise risk. The FDA said its review of animal data did not identify a mechanism explaining how GLP-1 medicines might increase NAION risk.

Is NAION the same as diabetic retinopathy?

No. NAION involves the optic nerve; diabetic retinopathy damages blood vessels in the retina, the light-sensitive tissue at the back of the eye. Both can threaten sight, but they are different conditions. Ozempic prescribing information also warns about diabetic retinopathy complications, and people with diabetes should keep their scheduled retinal screening appointments and discuss existing eye disease with their care team.

Changes in blood glucose can affect vision, but a new visual symptom should not be assumed to be a harmless adjustment to treatment. An eye professional can determine what is causing it and what care is needed.

Should you stop Ozempic because of the eyesight warning?

If you have no sudden visual symptoms, speak with your prescriber before changing or stopping treatment. The decision depends on your medical history, the reason for treatment, available alternatives and the benefits you receive, as well as the potential risk. Stopping diabetes medication without a replacement plan can make blood glucose harder to manage.

If sudden vision loss or rapidly worsening eyesight occurs, get urgent care first and tell the examining team about your treatment. UK guidance says semaglutide should be discontinued if NAION is confirmed. The FDA advises patients who have had NAION to discuss continuation with their clinician; its guidance to clinicians says to consider stopping the GLP-1 medicine unless its benefits clearly outweigh the risk.

Further research and regulatory review may refine estimates and clarify whether risk differs among medicines or patient groups. People in the UK can also report suspected medicine side effects through the MHRA Yellow Card scheme. A report can help safety monitoring, although it does not establish that a medicine caused the event.

Frequently asked questions

Can Ozempic cause blindness?

NAION can cause permanent vision loss, and UK and European regulators recognize it as a very rare risk associated with semaglutide. That does not mean most people taking Ozempic will lose their sight or that every vision problem is caused by the medicine.

Does the warning apply to Wegovy too?

Yes. Wegovy contains semaglutide, so the MHRA's semaglutide advice applies to it as well as Ozempic and Rybelsus.

What should I do if my vision suddenly changes?

Urgently attend an eye casualty department, if available, or A&E. Mention your medicines and when the symptoms began, even if the vision loss is only partial or affects one eye.